The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The company also raised Rs 270 crore investment from Temasek in 2019
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
Subscribe To Our Newsletter & Stay Updated
